A106 SAFETY OF USTEKINUMAB WITH AND WITHOUT CONCOMITANT CORTICOSTEROIDS OR IMMUNOSUPPRESSANTS IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN’S DISEASE

BACKGROUND: Ustekinumab (UST), a monoclonal antibody to IL-12 and 23, was recently approved for the treatment of moderate-severe CD. AIMS: Here we report safety data with and without concomitant use of Immunomodulators(IMM) and corticosteroids(CS) in induction and maintenance in pts pooled from the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Can Assoc Gastroenterol
Glavni autori: Sands, B E, Gasink, C, Jacobstein, D, Ott, E, Lang, Y, Ramachandran, P, Ghosh, S
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Paper Sessions
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6508235/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy009.106
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items